Cannabis Showed Promise for Crohn's Disease, but Evidence Remains Limited
In early clinical studies, cannabis improved Crohn's disease symptoms and activity scores, but low-dose CBD alone did not, and controlled trial data remains sparse.
Quick Facts
What This Study Found
The authors report on their own clinical research program alongside a broader literature review. In an observational study of 30 Crohn's disease patients, medical cannabis was associated with improved disease activity and reduced use of other medications.
In a subsequent placebo-controlled trial of 21 chronic Crohn's patients, 10 of 11 subjects receiving cannabis showed a decrease in Crohn's Disease Activity Index (CDAI) greater than 100 points, compared to 4 of 10 on placebo. Complete remission was achieved in 5 of 11 cannabis patients versus 1 of 10 placebo patients.
However, in a separate study, low-dose cannabidiol alone did not improve Crohn's disease activity. The review also covers preclinical evidence that the endocannabinoid system is involved in major immune events and that cannabinoids reduce histologic inflammation in mouse models of colitis.
Key Numbers
Observational study: 30 patients. Placebo-controlled trial: 21 patients, 10/11 on cannabis showed CDAI decrease >100 vs. 4/10 on placebo. Complete remission: 5/11 cannabis vs. 1/10 placebo. Low-dose CBD study: no effect on disease activity.
How They Did This
This is a narrative review combining the authors' own clinical trial results with a broader literature survey. It covers preclinical studies in murine colitis models, observational clinical data, and controlled trial results. The authors also discuss the historical use of cannabis for gastrointestinal conditions.
Why This Research Matters
Inflammatory bowel diseases like Crohn's are chronic, often debilitating conditions with limited treatment options. This review consolidates early evidence suggesting cannabis may reduce symptoms and disease activity, while also highlighting that low-dose CBD alone was insufficient and that much more research is needed.
The Bigger Picture
The endocannabinoid system plays a significant role in gut immune function, and early clinical results for cannabis in Crohn's disease are intriguing. However, the field still needs to determine optimal cannabinoid formulations, doses, and delivery methods before cannabis can be considered an established treatment for IBD.
What This Study Doesn't Tell Us
The clinical trials described were very small (21-30 patients). The placebo-controlled trial did not achieve statistical significance for remission. Symptom improvement may not correlate with objective mucosal healing. The review is narrative rather than systematic, and the authors are reviewing their own work.
Questions This Raises
- ?Which specific cannabinoids or combinations are most effective for Crohn's disease?
- ?Why did low-dose CBD alone fail while whole-plant cannabis showed benefit?
- ?Does cannabis achieve mucosal healing or only symptomatic relief?
Trust & Context
- Key Stat:
- 10 of 11 Crohn's patients on cannabis showed meaningful symptom improvement vs. 4 of 10 on placebo
- Evidence Grade:
- This is a narrative review incorporating small clinical trials. The results are promising but based on limited sample sizes.
- Study Age:
- Published in 2014. Larger trials of cannabis and cannabinoids for IBD have been conducted since, with mixed results.
- Original Title:
- Cannabis for inflammatory bowel disease.
- Published In:
- Digestive diseases (Basel, Switzerland), 32(4), 468-74 (2014)
- Authors:
- Naftali, Timna(8), Mechulam, Raphael, Lev, Lihi Bar, Konikoff, Fred M
- Database ID:
- RTHC-00837
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why did CBD alone not work for Crohn's disease?
The study used low-dose CBD, which may have been insufficient. Additionally, the therapeutic effect of cannabis in IBD may require multiple cannabinoids working together (the entourage effect) rather than CBD in isolation.
Is cannabis a replacement for IBD medications?
Based on current evidence, cannabis has not been established as a replacement for standard IBD treatments. The studies described were small and preliminary, and cannabis was used as an adjunct to existing therapy in most cases.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-00837APA
Naftali, Timna; Mechulam, Raphael; Lev, Lihi Bar; Konikoff, Fred M. (2014). Cannabis for inflammatory bowel disease.. Digestive diseases (Basel, Switzerland), 32(4), 468-74. https://doi.org/10.1159/000358155
MLA
Naftali, Timna, et al. "Cannabis for inflammatory bowel disease.." Digestive diseases (Basel, 2014. https://doi.org/10.1159/000358155
RethinkTHC
RethinkTHC Research Database. "Cannabis for inflammatory bowel disease." RTHC-00837. Retrieved from https://rethinkthc.com/research/naftali-2014-cannabis-for-inflammatory-bowel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.